Evidence map›Paper›PMID 19317426›Full record

ArticleBiochemistry2009

Steroid and protein ligand binding to cytochrome P450 46A1 as assessed by hydrogen-deuterium exchange and mass spectrometry.

Wei-Li Liao, Nathan G Dodder, Natalia Mast, Irina A Pikuleva, Illarion V Turko

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Biochemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03706885 (A Proof-of-Concept Clinical Research Study of Efavirenz in Patients With Alzheimer's Disease), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03706885 phase1completednot on this mapstarted 2018, after this paper: background citation

A Proof-of-Concept Clinical Research Study of Efavirenz in Patients With Alzheimer's Disease

TypeinterventionalSponsorCase Western Reserve UniversityRan2018 to 2022Enrolled5ConditionsAlzheimer Disease, Early OnsetArmsSustiva Pill
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Cholesterol in the retina: the best is yet to come.Progress in retinal and eye research · 2014
    Review
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Wei-Li LiaoCenter for Advanced Research in Biotechnology, University of Maryland Biotechnology Institute, Rockville, Maryland 20850, USA.
Nathan G Dodder
Natalia Mast
Irina A Pikuleva
Illarion V Turko
Case Western Reserve University · USNational Institute of Standards and Technology · USBiotechnology Institute · US

Funding

Structure and function of cholesterol metabolizing P450sR01GM062882 · NIGMS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI PIKULEVA, IRINA A · 2001 to 2019
$5.5M
Cholesterol-metabolizing P450s and Alzheimer's diseaseK02AG024336 · NIA · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI PIKULEVA, IRINA A · 2005 to 2009
$515k
NIA NIH HHS AG024336NIA NIH HHS K02 AG024336NIGMS NIH HHS GM062882NIGMS NIH HHS R01 GM062882
6 · The paper itself

Abstract

Cytochrome P450 46A1 (CYP46A1) is a key enzyme responsible for cholesterol elimination from the brain. This P450 can interact with different steroid substrates and protein redox partners. We utilized hydrogen-deuterium (H-D) exchange mass spectrometry for investigating CYP46A1-ligand interactions. First, we tested the applicability of the H-D exchange methodology and assessed the amide proton exchange in substrate-free and cholesterol-sulfate-bound P450. The results showed good correspondence to the available crystal structures and prompted investigation of the CYP46A1 interactions with the two steroid substrates cholesterol and 24S-hydroxycholesterol and the protein redox partner adrenodoxin (Adx). Compared to substrate-free P450, four peptides in cholesterol-bound CYP46A1 (65-80, 109-116, 151-164, and 351-361) and eight peptides in 24S-hydroxycholesterol-bound enzyme (50-64, 65-80, 109-116, 117-125, 129-143, 151-164, 260-270, and 364-373) showed altered deuterium incorporation. Most of these peptides constitute the enzyme active site, whereas the 351-361 peptide is from the region putatively interacting with the redox partner Adx. This also defines the proximal (presumably water) channel that opens in CYP46A1 upon substrate binding. Reciprocal studies of Adx binding to substrate-free and cholesterol-sulfate-bound CYP46A1 revealed changes in the deuteration of the Adx-binding site 144-150 and 351-361 peptides, active site 225-239 and 301-313 peptides, and in the 265-276 peptide, whose functional role is not yet known. The data obtained provide structural insights into how substrate and redox partner binding are coordinated and linked to the hydration of the enzyme active site.

Indexed as

Mass SpectrometryAdrenodoxinAmino Acid SequenceBinding SitesCholesterol EstersCytochrome P-450 Enzyme SystemDeuteriumHydrogenHydroxycholesterolsLigandsModels, MolecularMolecular Sequence DataOxidation-ReductionPeptide MappingProtein BindingProteins24-hydroxycholesterolAdrenodoxinCholesterol Esterscholesteryl sulfateCytochrome P-450 Enzyme SystemDeuteriumHydrogenHydroxycholesterolsLigandsProteinsSteroids

Identifiers

PMID19317426
PMCPMC2693120
OpenAlexW2019986105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.